The National Institutes of Health (NIH) is offering a funding opportunity through the Blueprint Neurotherapeutics Network (BPN) for small businesses engaged in small molecule drug discovery and development targeting disorders of the nervous system. This initiative, structured as a U44 Cooperative Agreement, allows projects to enter either the Discovery stage, focusing on optimizing promising compounds, or the Development stage, which emphasizes preclinical safety studies and Phase I clinical trials. The program is designed to facilitate innovative research and expedite the translation of new therapeutics from laboratory to clinical settings, with a strong emphasis on intellectual property management and collaboration with NIH-funded consultants and contract research organizations. Interested applicants must be U.S. small business concerns and can find more details, including application deadlines and contact information, at the provided NIH link, with the closing date for submissions set for August 18, 2026.